Alpha 2.0
Login Register
» Authors » H Suryapranata

H Suryapranata

Explore the profile of H Suryapranata including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 141
Citations 1879
Followers 0
Related Specialties
Cardiology & Vascular Diseases
General Medicine
Endocrinology
Top 10 Co-Authors
F Zijlstra
P W Serruys
M J de Boer
P J de Feyter
M van den Brand
J P Ottervanger
J C Hoorntje
J C A Hoorntje
A W J van t Hof
G De Luca
Published In
Neth Heart J
Eur Heart J
Am J Cardiol
Circulation
J Am Coll Cardiol
Affiliations
Soon will be listed here.
Recent Articles
1.
Final benefit of primary percutaneous coronary intervention for ST-elevation myocardial infarction in older patients: long-term results of a randomised trial
de Boer M, Ottervanger J, Vant Hof A, Hoorntje J, Suryapranata H, Zijlstra F
Neth Heart J . 2022 Sep; 30(12):567-571. PMID: 36112340
Background: Although the short-term benefit of primary percutaneous coronary intervention (PCI) in elderly patients with ST-elevation myocardial infarction (STEMI) has been demonstrated, the final long-term survival benefit is as yet...
2.
Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial
Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, Barbieri L, et al.
J Thromb Thrombolysis . 2021 Apr; 52(3):797-807. PMID: 33847862
Background: Gender differences in the thrombotic and bleeding risk have been suggested to condition the benefits of antithrombotic therapies in Acute Coronary Syndrome (ACS) patients, and mainly among those undergoing...
3.
ST-segment elevation myocardial infarction: Historical perspective and new horizons
Zijlstra F, Suryapranata H, de Boer M
Neth Heart J . 2020 Aug; 28(Suppl 1):93-98. PMID: 32780338
After a brief history of the emergence of modern therapy for acute ST-elevation myocardial infarction, we discuss the issues that dominate ongoing studies and are the focus of intense debates....
4.
Use, timing and outcome of coronary angiography in patients with high-risk non-ST-segment elevation acute coronary syndrome in daily clinical practice: insights from a 'real world' prospective registry
Badings E, Hermanides R, Van Der Sluis A, Dambrink J, Gosselink A, Kedhi E, et al.
Neth Heart J . 2018 Dec; 27(2):73-80. PMID: 30547413
Background: An early invasive strategy (EIS) is recommended in high-risk patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), defined as coronary angiography (CAG), within 24 h of admission. The aim of...
5.
NT-proBNP during and after primary PCI for improved scheduling of early hospital discharge
Schellings D, van t Hof A, Ten Berg J, Elvan A, Giannitsis E, Hamm C, et al.
Neth Heart J . 2016 Dec; 25(4):243-249. PMID: 27943177
Background: The Zwolle Risk Score (ZRS) identifies primary percutaneous coronary intervention (PPCI) patients at low mortality risk, eligible for early discharge. Recently, this score was improved by adding baseline NT-proBNP....
6.
Diagnosis of takotsubo cardiomyopathy is increasing over time in patients presenting as ST-elevation myocardial infarction
Otten A, Ottervanger J, Symersky T, Suryapranata H, de Boer M, Maas A
Neth Heart J . 2016 Jul; 24(9):520-9. PMID: 27412161
Background: Takotsubo cardiomyopathy often presents with the clinical signs of ST-elevation myocardial infarction (STEMI). The increase in scientific publications addressing this relatively rare condition may result in higher awareness and...
7.
Impact of neutrophil-to-lymphocyte ratio on periprocedural myocardial infarction in patients undergoing non-urgent percutaneous coronary revascularisation
Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Bellomo G, Marino P, et al.
Neth Heart J . 2016 Jun; 24(7-8):462-74. PMID: 27277659
Background: Pro-thrombotic conditions importantly influence myocardial perfusion and procedural results after percutaneous coronary intervention (PCI). The neutrophil-to-lymphocyte ratio (NLR) has emerged as a predictor of cardiovascular events and of long-term...
8.
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study
Nardin M, Verdoia M, Pergolini P, Rolla R, Barbieri L, Schaffer A, et al.
Nutr Metab Cardiovasc Dis . 2016 May; 26(7):567-574. PMID: 27134063
Background And Aims: New antithrombotic therapies have significantly improved the outcomes of patients with acute coronary syndrome (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits. However,...
9.
Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor
Barbieri L, Verdoia M, Pergolini P, Nardin M, Rolla R, Marino P, et al.
Nutr Metab Cardiovasc Dis . 2016 Feb; 26(4):352-8. PMID: 26857781
Background And Aim: High residual platelet reactivity (HRPR) is still an important challenge, despite the advent of new potent ADP-antagonists. Therefore it is of extreme importance to identify factors that...
10.
The extent of ST elevation and ST deviation as predictors of mortality in ST-segment elevation myocardial patients planned to undergo primary percutaneous coronary intervention
Postma S, Dambrink J, Gosselink A, Ottervanger J, Kolkman E, Ten Berg J, et al.
Int J Cardiol . 2015 Dec; 205:31-36. PMID: 26709137
Background: Only few data are available on the predictive value of ST deviation (both ST elevation and depression). Therefore, we have examined the predictive value of ST elevation and ST...